CD34 and graft versus host disease: In murine models, MSC-EVs enriched in CD73+ and CD34+ subpopulations have demonstrated the ability to reverse graft-versus-host disease (GvHD) and support recovery from hindlimb ischemia by attenuating Th1-driven inflammation (Mann et al., 2022).